A Striking Look into the Invisible World of Phase 1 Clinical Trials: A Book Review of Jill Fisher's Adverse Events

Abstract

It is her analysis of how the latter process is instrumental in not only providing the Phase 1 industry with ready access to a pool of dedicated volunteers but also serves to generate data that presents pharmaceutical products in the best and safest way, that demonstrates how social inequalities are exploited for systematic profiteering by the pharmaceutical sector. This quote succinctly encapsulates the argument laid out in Jill A. Fisher's "Adverse Events": the Phase 1 clinical trial industry in the US not only relies upon but also exploits the social inequalities of the society in which it operates. [Extracted from the article] Copyright of New Genetics & Society is the property of Routledge and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)